GlassScriptPhysician profile
Mark R Johnson
NPI 1578670931
$982.03
in general payments reported to CMS, 2019-2025
14 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $71.88 · 2021: $163 · 2022: $122 · 2023: $85.66 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $269.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $218.81 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $152.07 | 2019-2023 | Dificid, Zerbaxa, Recarbrio |
| Allergan, INC. | $144.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.63 | 2025 | |
| Janssen Pharmaceuticals, INC | $102.81 | 2021-2022 | |
| Pfizer INC. | $69.46 | 2019-2021 | |
| Amgen INC. | $29.40 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $28.68 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Avanir Pharmaceuticals, INC. | $27.87 | 2019 | |
| Boston Scientific Corporation | $23.89 | 2019 | |
| Janssen Biotech, INC. | $15.19 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2019 | |
| Lilly USA, LLC | $13.78 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.